Compare Amylx Pharmaceuticals Inc (AMLX) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs ProShares Ultra QQQ ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $17.3 (market cap $1.98B), while ProShares Ultra QQQ ETF trades at $90.16. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, ProShares Ultra QQQ ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | QLD | |
|---|---|---|
Market Cap | $1.98B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $18.70 | $100.53 |
52-Week Low | $7.64 | $57.16 |
Enterprise Value | $1.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
QLD trades at $93.70, up 0.59% with a bullish technical signal from moving averages. The ProShares Ultra QQQ ETF leverages Nasdaq-100 exposure, delivering over 10,000% total return since inception. Recent news highlights tech sector strength and QLD's role in growth portfolios. Support levels at $92 and resistance at $94 indicate tight trading range.
Outlook remains positive given tech earnings momentum and AI-driven market optimism. However, leveraged ETF structure amplifies volatility risks, with QLD experiencing 63.80% maximum drawdown historically. Investors should weigh amplified returns against heightened downside exposure in market corrections.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
